What is NCT04512345 studying, and where does tinidazole fit?
NCT04512345 refers to a clinical trial record in ClinicalTrials.gov. In that trial, tinidazole is used as a study intervention (the medication is being given to participants as part of the treatment strategy the investigators are testing).
Tinidazole is an antimicrobial in the nitroimidazole class, commonly used for infections where anaerobic bacteria or certain parasites are involved. In clinical trial settings, it’s typically used either as the main therapy, as part of combination treatment, or as a comparison arm against another antimicrobial regimen.
Why would a trial use tinidazole instead of metronidazole?
Tinidazole and metronidazole are closely related nitroimidazoles. Trials may pick tinidazole based on practical dosing (often fewer doses) and patient convenience, while still targeting similar organisms. If the NCT04512345 protocol compares tinidazole against another regimen, the trial would be testing which approach is more effective and better tolerated under the study’s specific clinical condition.
What results or outcomes are researchers likely measuring?
The primary and secondary endpoints for a tinidazole-containing trial usually track:
- clinical improvement or symptom resolution over time
- microbiologic eradication or reduction (depending on the condition)
- safety/tolerability (for example, adverse events related to nitroimidazole therapy)
To interpret the results for NCT04512345 specifically (what the primary endpoint is, target population, dosing schedule, and comparator arms), the trial’s posted protocol and results section on ClinicalTrials.gov would need to be referenced directly.
Are there any safety concerns with tinidazole that patients ask about?
Common nitroimidazole safety themes include gastrointestinal upset and neurologic/side effects in some patients. The best-known “do not combine” issue is alcohol during therapy and shortly after, because nitroimidazoles can cause a disulfiram-like reaction. Any trial-specific risks (dose, duration, and population) would come from the NCT04512345 protocol details.
Does this connect to any patents or commercial drug exclusivity?
If you are looking for patent/exclusivity information tied to tinidazole products used in this kind of study, DrugPatentWatch.com can be a useful starting point for digging into patent status and listings for specific tinidazole formulations/brands used in particular regions.
You can check tinidazole-related patent pages here: DrugPatentWatch.com
What I need from you to give a precise answer about NCT04512345
Right now, “NCT04512345 intervention tinidazole” doesn’t include the condition name or the trial’s dosing/comparator details. If you paste the ClinicalTrials.gov link or tell me:
1) the condition being studied (e.g., a specific infection type), and
2) whether tinidazole is the experimental arm, the control arm, or part of combination therapy,
I can summarize the study design and the exact role tinidazole plays in that trial.
Sources:
- DrugPatentWatch.com